Feasibility of Carbon Ion Radiotherapy in the Treatment of Gynecological Melanoma.
Aged
Female
GTP Phosphohydrolases
/ genetics
Genital Neoplasms, Female
/ pathology
Heavy Ion Radiotherapy
/ adverse effects
Humans
Melanoma
/ genetics
Membrane Proteins
/ genetics
Middle Aged
Neoplasm Recurrence, Local
/ pathology
Proto-Oncogene Proteins B-raf
/ genetics
Proto-Oncogene Proteins c-kit
/ genetics
Skin Neoplasms
/ genetics
Melanoma, Cutaneous Malignant
Gynecological melanoma
carbon ion radiotherapy
lower genital tract
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
14
12
2018
revised:
28
12
2018
accepted:
07
01
2019
entrez:
27
2
2019
pubmed:
26
2
2019
medline:
6
6
2019
Statut:
ppublish
Résumé
Malignant melanoma of the lower genital tract is a rare disease known to have a poor prognosis. Because of the high rate of distant metastasis and unsatisfactory survival benefit, a more conservative treatment approach, instead of extensive surgery, may be warranted. Gynecological melanoma is a radioresistant tumor, an ideal disease to test the biological efficacy of carbon ion radiotherapy (CIRT). To report our preliminary experience with CIRT in the treatment of gynecological melanoma at the National Center of Oncological Hadrontherapy (CNAO). Between January 2016 and February 2017, four patients were admitted for CIRT at CNAO. A case of cervical melanoma was treated with palliative aim because of large volume macroscopic disease, while three cases of vaginal melanoma were irradiated with a total dose of 68.8 Gy (relative biological effectiveness) in 16 fractions delivered over 4 weeks (4 days a week). The age of women ranged between 49 and 72 (median=60.5 years) years. Treatment was well tolerated in all patients and all women completed the scheduled treatment course. During CIRT, toxicity was mild. For patients with vaginal disease, local control was 10.23 and 12.6 months, while that for cervical malignant melanoma was 7.3 months. All patients experienced systemic progression, with median distant metastasis-free survival of 11.7 months. The median overall survival for the whole patient group was 11.41 months. In our first experiences, CIRT appears to be a safe non-invasive option for malignant melanoma of the lower genital tract, but more data and longer follow-up are necessary in order to evaluate the effectiveness and late effects.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant melanoma of the lower genital tract is a rare disease known to have a poor prognosis. Because of the high rate of distant metastasis and unsatisfactory survival benefit, a more conservative treatment approach, instead of extensive surgery, may be warranted. Gynecological melanoma is a radioresistant tumor, an ideal disease to test the biological efficacy of carbon ion radiotherapy (CIRT).
AIM
OBJECTIVE
To report our preliminary experience with CIRT in the treatment of gynecological melanoma at the National Center of Oncological Hadrontherapy (CNAO).
PATIENTS AND METHODS
METHODS
Between January 2016 and February 2017, four patients were admitted for CIRT at CNAO. A case of cervical melanoma was treated with palliative aim because of large volume macroscopic disease, while three cases of vaginal melanoma were irradiated with a total dose of 68.8 Gy (relative biological effectiveness) in 16 fractions delivered over 4 weeks (4 days a week).
RESULTS
RESULTS
The age of women ranged between 49 and 72 (median=60.5 years) years. Treatment was well tolerated in all patients and all women completed the scheduled treatment course. During CIRT, toxicity was mild. For patients with vaginal disease, local control was 10.23 and 12.6 months, while that for cervical malignant melanoma was 7.3 months. All patients experienced systemic progression, with median distant metastasis-free survival of 11.7 months. The median overall survival for the whole patient group was 11.41 months.
CONCLUSION
CONCLUSIONS
In our first experiences, CIRT appears to be a safe non-invasive option for malignant melanoma of the lower genital tract, but more data and longer follow-up are necessary in order to evaluate the effectiveness and late effects.
Identifiants
pubmed: 30804128
pii: 33/2/473
doi: 10.21873/invivo.11497
pmc: PMC6506293
doi:
Substances chimiques
Membrane Proteins
0
KIT protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
GTP Phosphohydrolases
EC 3.6.1.-
NRAS protein, human
EC 3.6.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
473-476Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Phys Med Biol. 1999 Jan;44(1):185-205
pubmed: 10071883
Phys Med Biol. 2000 Nov;45(11):3319-30
pubmed: 11098906
Obstet Gynecol. 2007 Aug;110(2 Pt 1):296-301
pubmed: 17666603
Melanoma Res. 2009 Aug;19(4):267-70
pubmed: 19525876
Obstet Gynecol. 2010 Dec;116(6):1358-65
pubmed: 21099603
Jpn J Clin Oncol. 2012 Aug;42(8):670-85
pubmed: 22798685
Phys Med Biol. 2012 Nov 21;57(22):7543-54
pubmed: 23104051
Phys Med Biol. 2013 Jun 7;58(11):3837-47
pubmed: 23681116
Int J Gynecol Cancer. 2013 Oct;23(8):1484-9
pubmed: 23945202
Technol Cancer Res Treat. 2014 Aug;13(4):303-14
pubmed: 24206209
J Radiat Res. 2014 Mar 1;55(2):343-50
pubmed: 24536019
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S117-22
pubmed: 24987924
Ann Surg Oncol. 2015;22(6):1959-66
pubmed: 25384702
Med Phys. 2015 Jan;42(1):263-75
pubmed: 25563266
Biomed Res Int. 2015;2015:303791
pubmed: 25695059
Phys Med. 2015 Jun;31(4):333-51
pubmed: 25840619
Med Phys. 2015 Sep;42(9):5287-300
pubmed: 26328978
Radiother Oncol. 2016 Aug;120(2):307-12
pubmed: 27394694
Cancer. 2017 Apr 15;123(8):1333-1344
pubmed: 28026870
Anticancer Res. 2018 Mar;38(3):1335-1341
pubmed: 29491057
Gynecol Oncol. 2018 Jul;150(1):180-189
pubmed: 29728261
J Obstet Gynaecol Can. 2019 Jun;41(6):762-771
pubmed: 30391279